Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Latest News
Cancer groups offer guidance on immune-related adverse events
Publish date:
March 9, 2018
hematologynews@frontlinemedcom.com
Pages
« first
1
2
3
4
5
Recommended Reading
Experimental PD-1/PARP inhibitor combo shows promise in solid tumors
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
New model predicts survival in atezolizumab-treated advanced urothelial carcinoma
MDedge Hematology and Oncology
Study: Test for PD-L1 amplification in solid tumors
MDedge Hematology and Oncology
Study explores biological implications of MHC-II expression in tumor cells
MDedge Hematology and Oncology
The T-cell repertoire in NSCLC: Therapeutic implications
MDedge Hematology and Oncology
Objective response rate correlates poorly with overall survival in checkpoint-inhibitor trials
MDedge Hematology and Oncology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Hematology and Oncology
Avelumab safety compares with other checkpoint inhibitors
MDedge Hematology and Oncology
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancer
MDedge Hematology and Oncology
Immuno-oncology
Patient & Survivor Care
Immunotherapy
Cellular Therapy
All Specialties
